Product Program year 2025 Source: CMS Open Payments

Zynlonta

Drug Oncology

NDC 79952-110-01

Open in the dashboard

General payments

$757,275

4,058 payments

Research payments

$2,753,490

1,012 payments

Through program year 2025, $757,275 in general payments and $2,753,490 in research payments were reported against Zynlonta (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2025 General $750,983 4,056
2025 Research $2,753,490 1,012
2024 General $6,292 2

Breakdown

Who paid General payments · program years 2024–2025
  1. ADC Therapeutics America, Inc. $728,320 4,052 payments
  2. Swedish Orphan Biovitrum AB $28,955 6 payments
Top recipients General payments · program year 2025
  1. Rafic Farah Medical Oncology · Seattle, WA $66,449 9% · 43 payments
  2. Cyrus Khan Hematology & Oncology · Pittsburgh, PA $54,254 7% · 38 payments
  3. Adolfo Diaz Hematology & Oncology · San Antonio, TX $34,835 5% · 28 payments
  4. Mark Fesler Hematology & Oncology · Saint Louis, MO $28,673 4% · 13 payments
  5. Yazan Samhouri Hematology & Oncology · Gilbert, AZ $28,290 4% · 24 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $472,165 64% · 953 practitioners
  2. Medical Oncology Internal Medicine $121,766 17% · 251 practitioners
  3. Hematology Internal Medicine $76,325 10% · 40 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $20,008 3% · 391 practitioners
  5. Physician Assistant, Medical Physician Assistant $9,438 1% · 70 practitioners

The top 5 of 70 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Pennsylvania $99,607 13% · 113 recipients
  2. Texas $89,703 12% · 234 recipients
  3. Washington $82,578 11% · 47 recipients
  4. Florida $57,270 8% · 272 recipients
  5. Missouri $44,170 6% · 65 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

4,058 general · 1,012 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record